Corticosteroid · Anti-inflammatory, Anti-allergic, Antiasthmatic, Dermatological agent
Also known as Mometasone Furoate, Nasonex, Elocon, Asmanex Twisthaler
KDIGO 2024 + manufacturer label
281 branded formulations and 358 fixed-dose combinations. Look up specific brands in the Drugs workspace.
Jan Aushadhi — generic available at GoI pharmacies
Mometasone furoate is a synthetic corticosteroid with potent anti-inflammatory, anti-allergic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors (GR) in target cells, forming a steroid-receptor complex that translocates to the nucleus and modulates gene transcription. This results in: (1) inhibition of phospholipase A2, reducing arachidonic acid release and downstream prostaglandin and leukotriene synthesis; (2) suppression of inflammatory cytokine production (IL-1, IL-2, IL-6, TNF-alpha, IFN-gamma); (3) decreased mast cell and eosinophil recruitment; and (4) reduced vascular permeability. Mometasone has a high topical-to-systemic potency ratio due to extensive first-pass hepatic metabolism and low systemic bioavailability.
FDA PLLR: Animal studies showed fetal harm at high systemic doses. Limited human data. Use during pregnancy only if benefit clearly outweighs risk. Budesonide has the most safety data in pregnancy among inhaled corticosteroids.
Minimal systemic absorption means negligible excretion in breast milk. Compatible with breastfeeding per AAP. Monitor infant for thrush if using inhalation.
Increased systemic exposure to mometasone, potentially leading to Cushing's syndrome or adrenal suppression, especially with prolonged use or high doses.
Monitor for signs of systemic corticosteroid effects. Consider reducing mometasone dose or using an alternative antiretroviral if prolonged co-administration is necessary. Use with caution.
Increased systemic exposure to mometasone, potentially leading to Cushing's syndrome or adrenal suppression, especially with prolonged use or high doses.
Monitor for signs of systemic corticosteroid effects. Consider reducing mometasone dose or using an alternative antifungal if prolonged co-administration is necessary. Use with caution.
Increased systemic exposure to mometasone, potentially leading to Cushing's syndrome or adrenal suppression, especially with prolonged use or high doses.
Monitor for signs of systemic corticosteroid effects. Consider reducing mometasone dose or using an alternative antifungal if prolonged co-administration is necessary. Use with caution.
CYP3A4 inducers may reduce systemic exposure of mometasone by increasing hepatic metabolism, potentially reducing therapeutic efficacy.
Monitor symptom control. May need to increase mometasone dose or switch to alternative therapy.
Source: Kimi deep-research + Cla
Corticosteroids suppress immune response, potentially reducing vaccine efficacy and increasing risk of infection from live attenuated organisms.
Avoid live vaccines during high-dose corticosteroid therapy. Inactivated vaccines are safe but may have reduced efficacy.
Source: Kimi deep-research + Cla
Both corticosteroids and NSAIDs increase GI ulceration and bleeding risk. Additive effect on gastric mucosal damage.
Use PPI or H2-blocker for GI protection if concurrent use necessary. Monitor for GI bleeding.
Source: Kimi deep-research + Cla
Additive systemic corticosteroid effects — increased risk of adrenal suppression, osteoporosis, hyperglycemia, immunosuppression.
Minimize total steroid exposure. If multiple routes needed, use lowest effective doses. Monitor for signs of adrenal suppression.
Source: Kimi deep-research + Cla
Increased systemic exposure to mometasone, potentially leading to Cushing's syndrome or adrenal suppression, especially with prolonged use or high doses.
Monitor for signs of systemic corticosteroid effects. Consider reducing mometasone dose or using an alternative antiretroviral if prolonged co-administration is necessary. Use with caution.
CYP3A4 inhibitors may increase systemic exposure of mometasone by reducing hepatic metabolism of the small fraction that is absorbed, potentially increasing risk of systemic corticosteroid effects (adrenal suppression, Cushingoid features).
Monitor for signs of corticosteroid excess. Consider reducing mometasone dose or switching to corticosteroid not metabolized by CYP3A4 (e.g., beclomethasone).
Source: Kimi deep-research + Cla
Potentially increased systemic exposure to mometasone, though less pronounced than with strong inhibitors. Risk of systemic corticosteroid effects may increase with high doses or prolonged use.
Monitor for signs of systemic corticosteroid effects, especially with prolonged use. Generally, dose adjustment is not required for short-term use.
Potentially increased systemic exposure to mometasone, though less pronounced than with strong inhibitors. Risk of systemic corticosteroid effects may increase with high doses or prolonged use.
Monitor for signs of systemic corticosteroid effects, especially with prolonged use. Generally, dose adjustment is not required for short-term use.
Potentially increased systemic exposure to mometasone, though less pronounced than with strong inhibitors. Risk of systemic corticosteroid effects may increase with high doses or prolonged use.
Monitor for signs of systemic corticosteroid effects, especially with prolonged use. Generally, dose adjustment is not required for short-term use.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Katzung, BNF, Nelson·Verified: 2026-05-18 · House clinical team·Cockpit curated: 2026-05-18